On October 2, WUXI BIO fell 3.39% in regular trading, trading at HK$54.3 per share, with turnover of HK$154 million.
Within the Life Sciences Tools & Services sector where WUXI BIO belongs, the overall sector showed broad weakness. Among individual stocks, WUXI APPTEC down 3.25%, GENSCRIPT BIO down 4.68%, INSILICO down 6.57%, WUXI XDC down 4.15%, XTALPI down 5.99%.
WUXI BIO is an investment holding company principally engaged in providing end-to-end solutions and services for biologics discovery, development and manufacturing to clients in the biologics industry. The company operates through two segments: the Biologics segment, focused on biologics discovery, development and manufacturing, and the WuXi XDC segment, providing CRDMO services for antibody-drug conjugates and various bioconjugate drugs.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)